	US 12,144,851 B2
	Vaccinal strategy
François Lang, Nantes (FR); and Catherine Rabu, Nantes (FR)
Assigned to INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); and UNIVERSITE DE NANTES, Nantes (FR)
Appl. No. 17/046,816
Filed by INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); and UNIVERSITÉ DE NANTES, Nantes (FR)
PCT Filed Apr. 12, 2019, PCT No. PCT/EP2019/059421 § 371(c)(1), (2) Date Oct. 12, 2020, PCT Pub. No. WO2019/197610, PCT Pub. Date Oct. 17, 2019.
Claims priority of application No. 18305456 (EP), filed on Apr. 13, 2018.
Prior Publication US 2021/0154282 A1, May 27, 2021
Int. Cl. C07K 16/00 (2006.01); A61K 39/00 (2006.01); A61K 47/65 (2017.01); C07K 14/705 (2006.01); C07K 14/73 (2006.01)

CPC A61K 39/0011 (2013.01) [A61K 47/65 (2017.08); C07K 14/70514 (2013.01); C07K 14/70517 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/876 (2018.08)]

12 Claims

1. A synthetic long peptide (SLP) comprising a CD4 class II peptide linked to a CD8 class I peptide by a peptidic linker,

wherein the peptidic linker is selected from the group consisting of the amino acid sequences LLSVG (SEQ ID NO:8), LLSVGG (SEQ ID NO:9) and LLSVGA (SEQ ID NO:191), and

wherein the CD4 class II peptide is linked at its C-terminal position to the peptidic linker and the CD8 class I peptide is linked at its N-terminal position to the peptidic linker, and

wherein the CD4 class II peptide and/or the CD8 class I peptide consists of a contiguous amino acid sequence selected from the group consisting of: SEQ ID NO:15 to 64, SEQ ID NO: 121 to 144 and SEQ ID NO:148 to 158.